Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: A German multicenter analysis on 9.294 patients

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 8, 2010, Pages 490-495

  Schutt M ^a   Kern, W ^b   Zimmermann, A ^c   Busch, P ^d   Kerner, W ^e   Voll, A ^f   Wagner, C ^g   Kann, P H ^h   Dapp, A ⁱ   Holl, R W ^j  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Reproduktionsmedizin und Pr natale Medizin   (Germany)

^c Diabetes Schwerpunktpraxis   (Germany)

^d Klinikum Offenbach   (Germany)

^e Heart and Diabetes Center Mecklenburg Vorpommern   (Germany)

^f Diabetes Schwerpunktpraxis   (Germany)

^g Diabeteszentrum Am Klinikum ^*  (Germany)

^h UNIVERSITY HOSPITAL MARBURG   (Germany)

ⁱ Diabeteszentrum Am Klinikum   (Germany)

^j UNIVERSITY OF ULM   (Germany)

more..

Author keywords

diabetes treatment; glycemic control; obesity; quality management

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DISEASE DURATION; FEMALE; GERMANY; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR;

EID: 77956960241     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1249024     Document Type: Article

References (29)

1. Action to Control Cardiovascular Risk in Diabetes Study Group,. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 2545-2559
2. ADVANCE Collaborative Group,. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 2560-2572
3. American Diabetes Association Standards of Medical Care in Diabetes 2007. Diabetes Care 2007 30 (Suppl. 1) S4-S41
4. Barnett A, Allsworth J, Jameson K, et al. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Res Med Opin 2007 23 1493-1507
5. Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med 2009 122 248-256
6. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 322 716-720
7. Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003 289 187-193
8. Golay A. The metformin and body weight. Int J Obes 2008 32 61-72
9. Harris SB, Worrall G, Macaulay A, et al. Diabetes Management in Canada: Baseline Results of the Group Practice Diabetes Management Study. Can J Diabetes 2006 30 131-137
10. Harris TB, Savage PJ, Tell GS, et al. Carrying the burden of cardiovascular risk in old age: associations of weight and weight change with prevalent cardiovascular disease, risk factors, and health status in the Cardiovascular Health Study. Am J Clin Nutr 1997 66 837-844
11. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. Arch Intern Med 2001 161 1194-1203
12. Herbst A, Kordonouri O, Schwab K, etal Holl RW for the DPV study group. Impact of physical activity on cardiovascular risk factors in children with type 1 diabetes: a multicenter study of 18392 patients. Diabetes Care 2007 30 203-209
13. Howard BV, Best LG, Galloway JM, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006 29 391-397
14. Huppertz E, Pieper L, Klotsche J, et al. Diabetes mellitus in German primary care: quality of glycaemic control and subpopulations not well controlled results of the DETECT study. Exp Clin Endocrinol Diabetes 2009 117 6-14
15. IDF Clinical Guidelines Task Force Global guideline for type 2 diabetes. International Diabetes Federation 2005 Brussels
16. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany results from the CODE-2 study. Dtsch Med Wochenschr 2001 126 585-589
17. McGill HC Jr, McMahan CA, Herderick EE, etal Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002 105 2712-2718
18. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003 290 1884-1890
19. Norris SL, Engelgau MM, Narayan KMV. Effectiveness of self-management training in type 2 diabetes. Diabetes Care 2001 24 561-587
20. Prospective Studies Collaboration. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009 373 1083-1096
21. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009 373 1765-1772
22. Rihl J, Biermann E, Standl E. Insulin resistance and type 2 diabetes: the IRIS-study. Diabetes und Stoffwechsel 2002 11 150-158
23. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006 444 847-853
24. Saaddine JB, Cadwell B, Gregg EW, et al. Improvement in diabetes processes of CARE and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006 144 465-474
25. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008 117 1945-1954
26. Scḧtt M, Kern W, Krause U, et al. for the DPV initiative Is the frequency of self blood glucose measurements related to longterm metabolic control? Multicenter analysis including 24500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006 114 384-388
27. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications. Arch Intern Med 2008 168 2070-2080
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 977-986
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853